Skip to content

Study · Animal study (in vivo) · rat · 2023

13 results

Effectiveness of analog of Humanin in ameliorating streptozotocin-induced diabetic nephropathy in Sprague Dawley rats.

Moin H, Shafi R, Ishtiaq A, Liaquat A, Majeed S, Zaidi NN

Peptides28 Apr 2023Cited by 10 (Europe PMC)

PMID37119975 (opens in a new tab)DOI10.1016/j.peptides.2023.171014 (opens in a new tab)PepBankPUB-37119975
Publisher pagePubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, [S14G]-humanin significantly reversed the elevated serum glucose.

    In plain wordsIn diabetic rats, a humanin analog lowered raised blood sugar compared with untreated diabetic rats.

    Peptide
    Humanin
    Outcome
    DecreaseSerum glucose
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    Biochemical analysis revealed that diabetic rats had markedly elevated levels of serum glucose, creatinine, BUN, TNF-α, and kidney tissue SOD.
    3 context sentences
    Summary · context
    All these parameters were significantly reversed in group C after administering [S14G]-humanin.
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, [S14G]-humanin significantly reversed the elevated serum creatinine.

    In plain wordsIn diabetic rats, a humanin analog lowered raised creatinine compared with untreated diabetic rats.

    Peptide
    Humanin
    Outcome
    DecreaseSerum creatinine
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    Biochemical analysis revealed that diabetic rats had markedly elevated levels of serum glucose, creatinine, BUN, TNF-α, and kidney tissue SOD.
    3 context sentences
    Summary · context
    All these parameters were significantly reversed in group C after administering [S14G]-humanin.
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, [S14G]-humanin significantly reversed the elevated BUN.

    In plain wordsIn diabetic rats, a humanin analog lowered raised BUN, a kidney marker, compared with untreated diabetic rats.

    Peptide
    Humanin
    Outcome
    DecreaseBlood urea nitrogen
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    Biochemical analysis revealed that diabetic rats had markedly elevated levels of serum glucose, creatinine, BUN, TNF-α, and kidney tissue SOD.
    3 context sentences
    Summary · context
    All these parameters were significantly reversed in group C after administering [S14G]-humanin.
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, [S14G]-humanin significantly reversed the elevated serum TNF-α.

    In plain wordsIn diabetic rats, a humanin analog lowered a raised inflammation marker compared with untreated diabetic rats.

    Peptide
    Humanin
    Outcome
    DecreaseSerum TNF-α
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    Biochemical analysis revealed that diabetic rats had markedly elevated levels of serum glucose, creatinine, BUN, TNF-α, and kidney tissue SOD.
    3 context sentences
    Summary · context
    All these parameters were significantly reversed in group C after administering [S14G]-humanin.
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, [S14G]-humanin significantly reversed the elevated kidney tissue SOD.

    In plain wordsIn diabetic rats, a humanin analog brought raised kidney SOD back down compared with untreated diabetic rats.

    Peptide
    Humanin
    Outcome
    DecreaseKidney tissue SOD
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Oxidative stress · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    Biochemical analysis revealed that diabetic rats had markedly elevated levels of serum glucose, creatinine, BUN, TNF-α, and kidney tissue SOD.
    3 context sentences
    Summary · context
    All these parameters were significantly reversed in group C after administering [S14G]-humanin.
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, [S14G]-humanin significantly reversed the decline in serum insulin.

    In plain wordsIn diabetic rats, a humanin analog restored the reduced insulin levels compared with untreated diabetic rats.

    Peptide
    Humanin
    Outcome
    IncreaseSerum insulin
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    Whereas, significant decline was detected in serum insulin and albumin levels. All these parameters were significantly reversed in group C after administering [S14G]-humanin.
    2 context sentences
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, [S14G]-humanin significantly reversed the decline in serum albumin.

    In plain wordsIn diabetic rats, a humanin analog restored the reduced albumin levels compared with untreated diabetic rats.

    Peptide
    Humanin
    Outcome
    IncreaseSerum albumin
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    Whereas, significant decline was detected in serum insulin and albumin levels. All these parameters were significantly reversed in group C after administering [S14G]-humanin.
    2 context sentences
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, [S14G]-humanin significantly reversed the upregulated expression of IL-18.

    In plain wordsIn diabetic rats, a humanin analog lowered a raised inflammation gene signal compared with untreated diabetic rats.

    Peptide
    Humanin
    Outcome
    DecreaseIL-18 expression
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    [S14G]-humanin treatment significantly reversed the expression of IL-18 and IL-1α
    2 context sentences
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, [S14G]-humanin significantly reversed the upregulated expression of IL-1α.

    In plain wordsIn diabetic rats, a humanin analog lowered a raised inflammation gene signal compared with untreated diabetic rats.

    Peptide
    Humanin
    Outcome
    DecreaseIL-1α expression
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    [S14G]-humanin treatment significantly reversed the expression of IL-18 and IL-1α
    2 context sentences
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, [S14G]-humanin did not significantly change the relative expression of IL-6.

    In plain wordsIn diabetic rats, a humanin analog did not clearly change IL-6 gene activity.

    Peptide
    Humanin
    Outcome
    No significant changeIL-6 expression
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    however, change in relative expression of IL-6, IL-1β, TNF-α and anti-inflammatory cytokines was insignificant (group C).
    2 context sentences
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, [S14G]-humanin did not significantly change the relative expression of IL-1β.

    In plain wordsIn diabetic rats, a humanin analog did not clearly change IL-1β gene activity.

    Peptide
    Humanin
    Outcome
    No significant changeIL-1β expression
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    however, change in relative expression of IL-6, IL-1β, TNF-α and anti-inflammatory cytokines was insignificant (group C).
    2 context sentences
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, [S14G]-humanin did not significantly change the relative expression of TNF-α.

    In plain wordsIn diabetic rats, a humanin analog did not clearly change TNF-α gene activity.

    Peptide
    Humanin
    Outcome
    No significant changeTNF-α expression
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    however, change in relative expression of IL-6, IL-1β, TNF-α and anti-inflammatory cytokines was insignificant (group C).
    2 context sentences
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.
  13. 13AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, [S14G]-humanin did not significantly change the relative expression of the anti-inflammatory cytokines.

    In plain wordsIn diabetic rats, a humanin analog did not clearly change anti-inflammatory gene activity.

    Peptide
    Humanin
    Outcome
    No significant changeAnti-inflammatory cytokine expression (IL-10, IL-1RN, IL-4)
    Study

    ratn: not reported in source

    Streptozotocin-induced diabetic nephropathy
    Comparator
    Diabetic control group
    Outcome group
    Inflammation markers · Kidney and urinary
    Studied dose
    0.4 mg/Kg/day · intraperitoneal · sixteen weeksAs given in this study (rat).

    Source sentences

    Summary
    however, change in relative expression of IL-6, IL-1β, TNF-α and anti-inflammatory cytokines was insignificant (group C).
    2 context sentences
    Summary · context
    Ninety Sprague Dawley (SD) rats were randomly segregated into three groups - A (control), B (disease control) and C (treatment).
    Summary · context
    Subsequently, diabetic rats in group C were injected with [S14G]-humanin intra-peritoneally (0.4 mg/Kg/day) for sixteen weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.